Development and Validation of UV Spectroscopic Method for Estimation of Baricitinib

Authors

  • Santosh Vilaschand Gandhi AISSMS College of Pharmacy, Pune-411001
  • Barkha Govindlal Kapoor AISSMS College of Pharmacy, Pune-411001

Abstract

A simple, sensitive and reproducible spectrophotometric method for the analysis of Baricitinib in pure form and in its dosage form has been developed. Baricitinib is a synthetic antineoplastic and immunomodulating  drug. Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. Developed method obeyed beer’s law in a concentration range of 10-60 µg/ml with a correlation coefficient (R2) of 0.993. Quantification was carried out at 250 nm. Percentage assay of Baricitinib was found to be close to 100 %. The results of analysis have been validated statistically and recovery studies confirmed the accuracy of the proposed method.

DOI

https://doi.org/10.22270/jddt.v9i4-s.3230

Published

15-08-2019
Statistics
Abstract Display: 1570
PDF Downloads: 1117

How to Cite

1.
Gandhi SV, Kapoor BG. Development and Validation of UV Spectroscopic Method for Estimation of Baricitinib. J. Drug Delivery Ther. [Internet]. 2019 Aug. 15 [cited 2025 Feb. 19];9(4-s):488-91. Available from: https://jddtonline.info/index.php/jddt/article/view/3230

How to Cite

1.
Gandhi SV, Kapoor BG. Development and Validation of UV Spectroscopic Method for Estimation of Baricitinib. J. Drug Delivery Ther. [Internet]. 2019 Aug. 15 [cited 2025 Feb. 19];9(4-s):488-91. Available from: https://jddtonline.info/index.php/jddt/article/view/3230